Intravitreal injection of bevacizumab for exsudative AMD with occult or minimal classic choroidal neovascularisation (CNV);Bevacizumab intravitreal zur behandlung okkulter und minimal klassischer choroidaler neovaskularisation (CNV) bei AMD

Klinische Monatsblatter fur Augenheilkunde

Volumn 225, Issue 9, 2008, Pages 818-824

  Maier, Mathias M ^a   Feucht, N ^a   Haas, K ^a   Fiore, B ^a   Winkler Von Mohrenfels, C ^a   Clos, A ^a   Lohmann, C ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Choroid; Retina; Vitreous

Indexed keywords

BEVACIZUMAB;

ADULT; ANGIOGRAPHY; ARTICLE; CLINICAL EXAMINATION; CLINICAL STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; EYE EXAMINATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OPTICAL COHERENCE TOMOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; VISUAL ACUITY;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; EXUDATES AND TRANSUDATES; FEMALE; HUMANS; INJECTIONS; MACULAR DEGENERATION; MALE; TREATMENT OUTCOME;

EID: 54749136579     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1027638     Document Type: Article

References (33)

1. Aiello LP, Brucker AJ, Chang S et al. Evolving guidelines for intravitreous injections. Retina 2004; 24: S3-S19
2. Aisenbrey S, Ziemssen F, Völker M et al. Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007; 245 (7): 941-948, Epub 2006 Dec 21
3. Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006; 113: 14-22
4. Avery RL, Pieramici DJ, Rabena MD et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363-372
5. Bernatchez PN, Rollin S, Soker S et al. Relative effects of VEGF-A and VEGF-C on endothelial cell proliferation, migration and PAF synthesis: Role of neuropilin-1. J Cell Biochem 2002; 85: 629-639
6. Brown DM, Kaiser PK, Michels M ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355 (14): 1432-1444
7. Chen Y, Wiesmann C, Fuh G et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 1999; 293: 685-881
8. Dhalla MS, Shah GK, Blinder KJ et al. Combined photodynamic therapy with verteporfin and intravitreal bevazicumab for choroidal neovascularization in age-related macular degeneration. Retina 2006; 26 (9): 988-993
9. Emerson MV, Lauer AK, Flaxel CJ et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 2007; 27 (4): 439-444
10. Gamulescu MA, Framme C, Sachs H. RPE-rip after intravitreal bevacizumab (Avastin) treatment for vascularised PED secondary to AMD. Graefes Arch Clin Exp Ophthalmol 2007; 245 (7): 1037-1040, Epub 2007 Feb 21
11. Goff MJ, Johnson RN, McDonald HR et al. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Retina 2007; 27 (4): 432-438
12. Goldstein M, Heilweil G, Barak A et al. Retinal pigment epithelial tear following photodynamic therapy for choroidal neovascularization secondary to AMD. Eye 2005; 19(12): 1315-1324
13. Gragoudas ES, Adamis AP, Cunningham Jr ET et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351 (27): 2805-2816
14. Hahn R, Sacu S, Michels S et al. Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macula degeneration. Ophthalmologe 2007; 104 (7): 588-593
15. Ishida S, Usui T, Yamashiro K et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 2003; 198: 483-489
16. Jaissle GB, Szurman P, Bartz-Schmidt KU. Recommendation for implementation of intravitreal injections- statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German professional Association of Ophthalmologists (BVA). Klin Monatsbl Augenheilkd 2005; 222: 390-395
17. Kook D, Wolf A, Neubauer AS et al. Retinal pigment epithelial tears after intravitreal injection of bevacizumab for AMD: Frequency and progress. Ophthalmologe 2007; Epub ahead of print
18. Ladewig MS, Ziemssen F, Jaissle G et al. Intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmologe 2006; 103 (6): 463-470
19. Michels S, Rosenfeld PJ, Puliafito CA et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005; 112: 1035-1047
20. Michels S, Rosenfeld PJ. Therapie der neovaskulären altersbedingten Makuladegeneration mit Ranibizumab/Lucentis. Klin Monatsbl Augenheilkd 2005; 222 (6): 480-484
21. Moshfeghi AA, Rosenfeld PJ, Puliafito CA et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 2006; 113 (11): 2002.e1-12, Epub 2006 Oct 5
22. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36: 331-335
23. Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355 (14): 1419-1431
24. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 2006; 19 (3): 361-372
25. Schmidt-Erfurth U, Laqua H, Schlotzer-Schrehard U et al. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol 2002; 120: 835-844
26. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C et al. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003; 44: 4473-4480
27. Shahar J, Avery RL, Heilweil G et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006; 26: 262-269
28. Spaide RF, Laud K, Fine HF et al. Intravitreal bevazicumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006; 26: 383-390
29. Takeda A, Hata Y, Shiose S et al. Suppression of experimental choroidal neovascularization utilizing KDR selective receptor tyrosine kinase inhibitor. Graefes Arch Clin Exp Ophthalmol 2003; 241: 765-772
30. TAP Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two year results of 2 randomized clinical trials-TAP Report 2. Arch Ophthalmol 2002; 119: 198-207
31. Thakker GD, Hajjar DP, Muller WA et al. The role of phospatidylinositol 3-kinase in vascular endothelial growth factor signaling. J Biol Chem 1999; 274: 10002-10007
32. Chakravarthy U, Adamis AP, Cunningham Jr ET et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006; 113 (9): 1508.e1-25, Epub 2006 Jul 7
33. Weinberger AW, Thiel M, Mohammadi B et al. Retinal pigment epithelium tears after intravitreal bevacizumab in pigment epithelium detachment. Am J Ophthalmol 2007; 144 (2): 294-296